Early onset diagnosis in Alzheimer's disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid

PCA-assisted direct diagnosis of Aβ proteins for Alzheimer's disease using non-metallic SERS platform of graphitic carbon nitride@metal-organic framework

Here, we explored a non-metallic surface enhanced Raman scattering (SERS) platform based on graphitic carbon nitride@metal-organic framework (g-C3N4@MOF) for the sensitive direct diagnosis of Aβ proteins, assisted by principal component analysis (PCA). By systematically optimizing the deposition voltage and time, we successfully achieved a uniform coating of g-C3N4 nanosheets over a large-area copper foil during the initial electrodeposition step. Subsequently, a homogeneous layer of flower-like MOF structures was deposited onto the g-C3N4 nanosheets through a secondary electrodeposition process. This cooperation of g-C3N4 nanosheets and flower-like MOF not only significantly enlarged the effective area for molecular enrichment but also promoted charge transfer through energy-level matching between the two materials. The characteristic SERS spectra of Aβ40 and Aβ42, enhanced by the g-C3N4@MOF composite substrate, were recorded and classified using PCA to extract informative features of these important biomarkers. This research exploits a new avenue for the clinical assay of neurodegenerative diseases by extracting informative features of key biomarkers.

Harnessing Photo-Energy Conversion in Nanomaterials for Precision Theranostics

The rapidly advancing field of theranostics aims to integrate therapeutic and diagnostic functionalities into a single platform for precision medicine, enabling the simultaneous treatment and monitoring of diseases. Photo-energy conversion-based nanomaterials have emerged as a versatile platform that utilizes the unique properties of light to activate theranostics with high spatial and temporal precision. This review provides a comprehensive overview of recent developments in photo-energy conversion using nanomaterials, highlighting their applications in disease theranostics. The discussion begins by exploring the fundamental principles of photo-energy conversion in nanomaterials, including the types of materials used and various light-triggered mechanisms, such as photoluminescence, photothermal, photoelectric, photoacoustic, photo-triggered SERS, and photodynamic processes. Following this, the review delves into the broad spectrum of applications of photo-energy conversion in nanomaterials, emphasizing their role in the diagnosis and treatment of major diseases, including cancer, neurodegenerative disorders, retinal degeneration, and osteoarthritis. Finally, the challenges and opportunities of photo-energy conversion-based technologies for precision theranostics are discussed, aiming to advance personalized medicine.

Rational Design of Long-Circulating Bright Fluorescent Probe for In Vivo Imaging of Amyloid-β Plaques in Alzheimer's Disease

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the pathological accumulation of amyloid-β (Aβ) plaques, which serve as crucial biomarkers for disease diagnosis and therapeutic evaluation. While fluorescence imaging has emerged as a powerful technique for Aβ detection, current probes face limitations in clinical application due to insufficient photostability and short blood half-life, resulting in compromised signal-to-noise ratios (SNRs) and imaging resolution. Herein, two bright quinoxalinone-based fluorescent probes (QNO-AD-PEGs) were presented, which incorporate hydrophilic poly(ethylene glycol) (PEG) chains for enhanced biocompatibility and an Aβ-specific N,N-dimethylaminophenyl recognition unit. QNO-AD-PEG1 demonstrated exceptional binding affinity for Aβ42 aggregates (Kd = 42 nM) and a remarkable 49-fold fluorescence enhancement upon target engagement, with a quantum yield (ΦAβ) of 11.45%. In vivo imaging revealed that QNO-AD-PEG1 effectively crossed the blood-brain barrier (BBB) and exhibited a prolonged half-life (315 min). Notably, the probe successfully visualized age-dependent Aβ plaque progression in AD mouse models. This study presents a significant breakthrough in molecular imaging for neurodegenerative diseases, offering a versatile tool for both fundamental AD research and potential clinical applications.

Direct and selective nanosensor for amyloid-β oligomers in serum for Alzheimer's disease diagnosis

The rising prevalence of Alzheimer's disease (AD) highlights an urgent need for ultra-sensitive diagnostic tools that facilitate early detection and intervention. Soluble Aβ oligomers (AβOs) have emerged as a key focus due to their specificity for AD pathology. This study introduces a magnetic nanoplatform-based ultrasensitive diagnostic assay for AβO detection, utilizing a novel custom-designed AβO-selective fluorophore, named O-SLM. This innovative approach achieves a sensitivity nearly tenfold greater than that of a comparative ELISA kit, with a detection limit as low as 25 fM. The assay requires minimal sample volumes and streamlines the protocol by omitting detection antibodies. It effectively distinguishes AD patients from healthy individuals through serum AβO quantification, demonstrating the versatility of our ultra-sensitive assay across various biomarkers.

Binding activated single molecule burst analysis highlights amyloid sensing interaction of dye SYPRO orange

Mode of interaction between fluorescent probe and local binding site on fibril architecture is central to the design of efficient amyloid sensors. SYPRO orange (SO) is reported to have two binding modes with two distinct binding configurations, namely weakly bound inclined and strongly bound surface hugging populations. Though two distinct sites for non-radiative relaxation, i.e. central π-bridge site and the electron donor amino site is evident from the molecular framework, it is unclear which site dictates fluorescence enhancement upon binding. We recommend employing the inherent sensitivity of fluorescence lifetime to alterations in non-radiative pathways for different binding configurations. In this contribution an attempt has been made to segregate binding activated single molecule bursts recorded with pulsed excitation into requisite weak and strong binding events, which were subsequently correlated with their corresponding excited state lifetimes. Comparison of fluorescence decays for these two binding modes suggest minor role of non-radiative relaxation at π-bridge site in deciding excited state decay of bound SO molecules. On the contrary, plausible hydrophobic interaction of aliphatic tails at the electron donor site with the fibril imparts configurational restrain at the amino group site, hindering its non-radiative pathways leading to increased fluorescence intensity and lifetime. This sensing behaviour of SO is consistent for fibrils of amyloidogenic proteins lysozyme and insulin. Present work has the relevance in the rational design of amyloid sensor as well as better super-resolution imaging probes for localization microscopy.

Chiral Bimetallic Pt@Au Octapods with Spiral Four-Petal Flower-Like Symmetric Configuration as Sensitive SERS Probes

Here, we synthesized chiral bimetallic Pt@Au octapods by using l/d-cysteine-threonine (CT) dipeptide as chiral ligands. These had a distinct spiral four-petal flower-like symmetric configuration with a twisted concave morphology on each facet. The twisted concave structure of the Pt@Au octapods facilitated intraparticle coupling, resulting in highly concentrated electric fields within the concave regions, thus creating "hot spots" that produced a potent surface-enhanced Raman scattering (SERS) effect. The l-Pt@Au octapods showed a nearly twofold stronger SERS response to Aβ40 and Aβ42 monomers and fibrils than the d-Pt@Au octapods. The different association constants arose from the unique chiral recognition capabilities of the CT ligands on the surfaces of the l-Pt@Au octapods, which allowed them to form specific hydrogen bonds with Aβ40 and Aβ42 monomers and fibrils, producing significant differences in their Raman spectra. The data from clinical cerebrospinal fluid (CSF) samples showed that the quantitative analysis of the Aβ42/Aβ40 ratio with Raman spectroscopy can be used as an effective biomarker for the early diagnosis of Alzheimer's disease (AD), with a cut-off value of 0.085. Our results pave the way for the use of chiral nanomaterials with strong optical activities in the development of clinical testing instruments with biomedical applications.

Body fluid diagnostics using activatable optical probes

In vitro diagnostics often detects biomarkers in body fluids (such as blood, urine, sputum, and cerebrospinal fluids) to identify life-threatening diseases at an early stage, monitor overall health, or provide information to help cure, treat, or prevent diseases. Most clinically used optical in vitro diagnostic tests utilize dye-labeled biomolecules for biomarker recognition and signal readout, which typically involve complex steps and long processing times. Activatable optical probes (AOPs), which spontaneously activate their optical signals only in the presence of disease biomarkers, offer higher signal-to-background ratios and improved detection specificity. They also have the potential to simplify detection procedures by eliminating multiple washing steps. In this review, we summarize recent advances in the use of AOPs for pre-clinical and clinical body fluid diagnostics across various diseases, including cancer, nephro-urological disorders, infectious diseases, and digestive diseases. We begin by discussing the molecular design strategies of AOPs to achieve different optical signal readouts and biomarker specificity. We then highlight their diagnostic applications in various disease models and body fluids. Finally, we address the challenges and future perspectives of AOPs in enhancing body fluid diagnostics and advancing precision medicine.

A Nonconsumptive Fluorescent Probe for Precise Detection of Hydrogen Peroxide in Nonalcoholic Fatty Liver Disease and Inflammation

Hydrogen peroxide (H2O2) plays a vital role in various physiological and pathological processes. Thus, fluorescent probes of H2O2 are powerful tools for the investigation of H2O2-related diseases. However, developing fluorescent probes that do not irreversibly consume H2O2 presents a significant challenge. In this work, we introduce carbonate ester as a nonconsumptive recognizing molecule to construct RES-6C as a novel fluorescent probe of H2O2. RES-6C exhibited a selective and sensitive turn-on fluorescence response to H2O2, enabling the detection of H2O2 in cells without disturbing the cellular redox status. RES-6C has been applied to study nonalcoholic fatty liver disease, revealing that peroxisomes and mitochondria contribute to H2O2 production to a similar extent during very-long-chain fatty acid metabolism for the first time. It has also enabled fluorescent imaging of H2O2 in the LPS-induced inflammation mouse model. Overall, RES-6C serves as a versatile tool to monitor H2O2 in tissues and in vivo, providing new insights into the design of probes for H2O2.

Mapping Dynamic Protein Clustering with AIEgen-Active Chemigenetic Probe

Protein clustering/disassembling is a fundamental process in biomolecular condensates, playing a crucial role in cell fate decision and cellular homeostasis. However, the inherent features of protein clustering, especially for its reversible behavior and subtle microenvironment variation, present significant hurdles in probe chemistry for tracking protein clustering dynamics. Herein, we report a bilateral-tailored chemigenetic probe, in which an "amphiphilic" aggregate-induced emission luminogen (AIEgen) QMSO3Cl is covalently conjugated to a protein tag that is genetically fused to protein-of-interest (POI). Prior to target POI, the "amphiphilic" AIE-active QMSO3Cl achieves a completely dark state in both aqueous biological environment and lipophilic organelles, thereby ensuring an ultra-low intrinsic background interference. Upon reaching POI, the combination of synthetic molecule and genetically encoded protein allows for protein clustering-dependent ultra-sensitive response, with a substantial lighting-up fluorescence (67.5-fold) as protein transitions from disassembling to clustering state. Such ultra-high signal-to-noise ratio enables to monitor the dynamic and fate of inositol requiring enzyme 1 (IRE1) clustering/disassembling under both acute and chronic endoplasmic reticulum (ER) stress in living cells. For the first time, we have demonstrated the use of chemigenetic probe to reveal therapy-induced ER stress and screen drugs in a three-dimensional scenario: microviscosity change, clustering dynamic, and cluster morphology. This chemigenetic probe design strategy would greatly facilitate the advancement of mapping protein dynamics in cell homeostasis and medicine research.

Electrochemical Biosensors for the Detection of Exosomal microRNA Biomarkers for Early Diagnosis of Neurodegenerative Diseases

Early and precise diagnosis of neurodegenerative disorders like Alzheimer's (AD) and Parkinson's (PD) is crucial for slowing their progression and enhancing patient outcomes. Exosomal microRNAs (miRNAs) are emerging as promising biomarkers due to their ability to reflect the diseases' pathology, yet their low abundance poses significant detection hurdles. This review article delves into the burgeoning field of electrochemical biosensors, designed for the precise detection of exosomal miRNA biomarkers. Electrochemical biosensors offer a compelling solution, combining the sensitivity required to detect low-abundance biomarkers with the specificity needed to discern miRNA profiles distinctive to neural pathological states. We explore the operational principles of these biosensors, including the electrochemical transduction mechanisms that facilitate miRNA detection. The review also summarizes advancements in nanotechnology, signal enhancement, bioreceptor anchoring, and microfluidic integration that improve sensor accuracy. The evidence of their use in neurodegenerative disease diagnosis is analyzed, focusing on the clinical impact, diagnostic precision, and obstacles faced in practical applications. Their potential integration into point-of-care testing and regulatory considerations for their market entry are discussed. Looking toward the future, the article highlights forthcoming innovations that might revolutionize early diagnostic processes. Electrochemical biosensors, with their impressive sensitivity, specificity, and point-of-care compatibility, are on track to become instrumental in the early diagnosis of neurodegenerative diseases, possibly transforming patient care and prognosis.

Visualization of Oxidative Stress in the Early Stage of Alzheimer's Disease with a NIR-IIb Probe

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is associated with the complete loss of cognition, and its pathogenesis has been suggested to be closely linked to oxidative stress in the early stage. However, there is currently a lack of effective methods to provide direct evidence for dynamic development of the oxidative stress status during AD progression. Herein, through manipulating the multiple energy transfer between 4f electronic levels of lanthanide ions (Ln3+), we proposed an energy interception strategy to construct activatable NIR-IIb nanoprobe for visualizing oxidative stress level. By utilizing an organic molecule, A1094 that absorbs light at wavelength matching the emission of Nd3+ and Yb3+, NIR-IIb emission from Er3+ can be modulated upon the response of A1094 to oxidative species. This nanoprobe can not only clearly outline and distinguish oxidative stress regions in AD brains with adjacent age but also provide fast feedback on the efficacy of early interventional treatment for AD.

Human serum albumin-3-amino-1-propanesulfonic acid conjugate inhibits amyloid-β aggregation and mitigates cognitive decline in Alzheimer's disease

Alzheimer's disease (AD) is the most commonly occurring brain disorder, characterized by the accumulation of amyloid-β (Aβ) and tau, subsequently leading to neurocognitive decline. 3-Amino-1-propanesulfonic acid (TPS) and its prodrug, currently under clinical trial III, serve as promising therapeutic agents targeting Aβ pathology by specifically preventing monomer-to-oligomer formation. Inspired by the potency of TPS prodrug, we hypothesized that conjugating TPS with human serum albumin (HSA) could enhance brain delivery and synergistically inhibit Aβ aggregation in mild to moderate AD. Thus, we prepared and extensively characterized HSA-TPS (h-TPS) conjugate using an eco-friendly coupling method. In vitro studies on Aβ aggregation kinetics and AFM imaging revealed significant prevention of Aβ aggregation. Additionally, h-TPS significantly reduced Aβ-induced neurotoxicity and H2O2-mediated reactive oxygen species (ROS) stress in SH-SY5Y cells. Moreover, h-TPS administration improved blood-brain barrier permeability and cellular uptake into neuronal cells as well as showed in vivo uptake inside the brain within 1 h. In vivo studies using an Aβ1-42-induced acute AD rat model exhibited a dose-dependent significant reduction in hippocampal Aβ levels and restoration of declined spatial learning and memory with h-TPS treatment. Overall, findings suggest that h-TPS conjugate might be a promising neuroprotective agent for preventing Aβ aggregation in mild to moderate AD.

Naphthalimide-derived fluorogenic SNAP probe for real-time monitoring of protein degradation

We developed the fluorogenic SNAP probe BGAN-8C to monitor protein degradation. It exhibited a 6-fold fluorescence enhancement upon binding with SNAP-tag. After the SNAP protein is degraded, the fluorescence of the released probe is quenched due to aggregation. BGAN-8C was successfully employed to monitor the degradation of mODC in live cells, offering a new tool for studying protein dynamics.

Plasmalogens Improve Lymphatic Clearance of Amyloid Beta from Mouse Brain and Cognitive Functions

Amyloid beta (Aβ) is a neuronal metabolic product that plays an important role in maintaining brain homeostasis. Normally, intensive brain Aβ formation is accompanied by its effective lymphatic removal. However, the excessive accumulation of brain Aβ is observed with age and during the development of Alzheimer's disease (AD) leading to cognitive impairment and memory deficits. There is emerging evidence that plasmalogens (Pls), as one of the key brain lipids, may be beneficial for AD and cognitive aging. Here, we studied the effects of Pls on cognitive functions and the lymphatic clearance of Aβ from the brain of AD mice and mice of different ages. The results showed that Pls effectively reduce brain Aβ levels and facilitate learning in aged but not old mice. In AD mice, Pls improve the lymphatic clearance of Aβ that is accompanied by an increase in general motor activity and an improvement of the emotional status and learning ability. Thus, these findings suggest that Pls could be a promising candidate for the alternative or concomitant therapy of AD and age-related brain diseases to enhance the lymphatic clearance of Aβ from the brain and cognitive functions.

AND-Gate Logic Förster Resonance Energy Transfer/Magnetic Resonance Tuning Nanoprobe for Programmable Antitumor Immunity Imaging

Simultaneous detection of different biomarkers related to the spatiotemporally dynamic immune events is of particular importance for the accurate evaluation of antitumor immune effects. Here, we have developed an AND-gate logic dual resonance energy transfer nanoprobe (named DRET) for dynamic monitoring of programmed CD8+ T cell activation and tumor cell apoptosis. Immunotherapy-induced granzyme B secretion from CD8+ T cells and the subsequent caspase-3 release from apoptotic tumor cells individually activate one of the tiers of the "AND-gate" logic DRET. The resulting fluorescence recovery and magnetic resonance T1 enhancement can be used for precise immunomodulatory drug screening, early efficacy prediction, and immune stratification. Particularly, not only "Responders" can be distinguished from "Non-responders", but also "Acquired resistance" can be identified from "Maintain responders", providing a novel approach to put forward the accurate evaluation of antitumor immunity.

Merocyanines: Electronic Structure and Spectroscopy in Solutions, Solid State, and Gas Phase

Merocyanines, owing to their readily tunable electronic structure, are arguably the most versatile functional dyes, with ample opportunities for tailored design via variations of both the donor/acceptor (D/A) end groups and π-conjugated polymethine chain. A plethora of spectral properties, such as strong solvatochromism, high polarizability and hyperpolarizabilities, and sensitizing capacity, motivates extensive studies for their applications in light-converting materials for optoelectronics, nonlinear optics, optical storage, fluorescent probes, etc. Evidently, an understanding of the intrinsic structure-property relationships is a prerequisite for the successful design of functional dyes. For merocyanines, these regularities have been explored for over 70 years, but only in the past three decades have these studies expanded beyond the theory of their color and solvatochromism toward their electronic structure in the ground and excited states. This Review outlines the fundamental principles, essential for comprehension of the variable nature of merocyanines, with the main emphasis on understanding the impact of internal (chemical structure) and external (intermolecular interactions) factors on the electronic symmetry of the D-π-A chromophore. The research on the structure and properties of merocyanines in different media is reviewed in the context of interplay of the three virtual states: nonpolar polyene, ideal polymethine, and zwitterionic polyene.

A mitochondria targeting, de novo designed, aggregation-induced emission probe for selective detection of neurotoxic amyloid-β aggregates

A striking issue is the scarcity of imaging probes for the early diagnosis of Alzheimer's disease. For the development of Aβ biomarkers, a mitochondria targeting, de novo designed, aggregation-induced emission (AIE) probe Cou-AIE-TPP+ is constructed by engineering the aromatic coumarin framework into the bridge of electron donor-acceptor-donor tethered with a lipophilic cationic triphenylphosphonium (TPP+) group. The synthesized Cou-AIE-TPP+ probe exhibits biocompatibility, noncytotoxicity, and a huge Stokes shift (124 nm in PBS). Cou-AIE-TPP+ has respectable fluorescence augmentation inside the aggregated Aβ40 in comparison with monomeric Aβ40 with a high binding affinity (Kd = 83 nM) to Aβ40 aggregates, is capable of detecting the kinetics of amyloid aggregation, and is superior to the gold standard probe thioflavin T. Fluorescence lifetime and brightness are also augmented when the probe Cou-AIE-TPP+ binds with Aβ aggregates in PBS. Cou-AIE-TPP+ (λem 604 nm) selectively targets and images neuronal cell mitochondria, is useful to monitor mitochondrial morphology alteration and damage during Aβ40-induced neurotoxicity, recognizes neurotoxic Aβ fibrils, and is highly colocalized with thioflavin T, showing a decent Pearson correlation coefficient of 0.91 in the human neuroblastoma SH-SY5Y cell line. These findings indicate that the mitochondria targeting, de novo designed, functional AIE-based solvatofluorochromic Cou-AIE-TPP+ probe is a promising switch on biomarkers for fluorescence imaging of Aβ aggregates and to monitor mitochondrial morphology change and dysfunction during Aβ-induced neurotoxicity, which may offer imperative direction for the advancement of compelling AIE biomarkers for targeted early stage Aβ diagnosis in the future.

Unveiling the potential of molecular imprinting polymer-based composites in the discovery of advanced drug delivery carriers

Molecularly imprinted polymers (MIPs) are polymeric matrices that can mimic natural recognition entities, such as antibodies and biological receptors. Molecular imprinting of therapeutics is very appealing in the design of drug delivery systems since the specific and selective binding sites created within the polymeric matrix turn these complex structures into value-added carriers with tunable features, notably high drug-loading capacity and good control of payload release. MIPs possess considerable promise as synthetic recognition elements in 'theranostics'. Moreover, the high affinity and specificity of MIPs make them more advantageous than other polymer-based nanocomposites. This review summarizes the present state-of-the-art of MIP-based delivery systems for the targeted delivery of bioactives, with current challenges and future perspectives.

An in situ-activated and chemi-excited photooxygenation system based on G-poly(thioacetal) for Aβ1-42 aggregates

The abnormal aggregation of Aβ proteins, inflammatory responses, and mitochondrial dysfunction have been reported as major targets in Alzheimer's disease (AD). Photooxygenation of the amyloid-β peptide (Aβ) is viewed as a promising therapeutic intervention for AD treatment. However, the limitations of the depth of the external light source passing through the brain and the toxic side effects on healthy tissues are two significant challenges in the photooxidation of Aβ aggregates. We proposed a method to initiate the chemical stimulation of Aβ1-42 aggregate oxidation through H2O2 and correct the abnormal microenvironment of the lesions by eliminating the cascading reactions of oxidative stress. The degradable G-poly(thioacetal) undergoes cascade release of cinnamaldehyde (CA) and thioacetal triggered by endogenous H2O2, with CA in turn amplifying degradation by generating more H2O2 through mitochondrial dysfunction. A series of novel photosensitizers have been prepared and synthesized for use in the photodynamic oxidation of Aβ1-42 aggregates under white light activation. The nanoparticles (BD-6-QM/NPs) self-assembled from BD-6-QM, bis[2,4,5-trichloro-6-(pentoxycarbonyl) phenyl] ester (CPPO), and G-poly(thioacetal) not only exhibit H2O2-stimulated controlled release but also can be chemically triggered by H2O2 to generate singlet oxygen to inhibit Aβ1-42 aggregates, reducing the Aβ1-42-induced neurotoxicity.

Modulation of AIE and Intramolecular Charge Transfer of a Pyrene-Based Probe for Discriminatory Detection and Imaging of Oligomers and Amyloid Fibrils

Oligomers and amyloid fibrils formed at different stages of protein aggregation are important biomarkers for a variety of neurodegenerative diseases including Alzheimer's and Parkinson's diseases. The development of probes for the sensitive detection of oligomeric species is important for early stage diagnosis of amyloidogenic diseases. Many small molecular dyes have been developed to probe the dynamic growth of amyloid fibrils. However, there is a lack of discriminatory detection strategies to monitor the dynamics of both oligomers and amyloid fibrils based on the differential modulation of the photophysical properties of a single dye. Here we report a pyrene-based intramolecular charge transfer (ICT) dye with large Stokes shifted red-emitting aggregation induced emission (AIE) for monitoring the dynamic populations of both oligomers and fibrils during the aggregation of hen egg white lysozyme (HEWL) protein. At the early stage of protein aggregation, the accumulation of HEWL oligomers results in a rapid and substantial increase in the red AIE intensity at 660 nm. Later, as the oligomers transform into mature fibrils, the dye exhibits a distinct photophysical change. Binding of the dye to HEWL fibrils strongly suppresses the red AIE and enhances ICT emission. This is evidenced by a gradual decrease in the AIE intensity (∼660 nm) and an increase in LE (∼490 nm) and ICT (∼540 nm) emission intensities during the later stages of protein aggregation. Thus, the dye provides simultaneous measurements of the population dynamics of both HEWL oligomers and fibrils during protein aggregation based on the discriminatory modulation of AIE and ICT of the dye. The dye also enables imaging of both HEWL oligomers and fibrils simultaneously using different emission channels in super-resolution confocal fluorescence microscopy.

Hierarchical Integration of Curcumin-Loaded CaCO3 Nanoparticles and Black Phosphorus Nanosheets in Core/Shell Nanofiber for Cranial Defect Repair

Reconstruction and healing of large craniofacial bone defects are major clinical challenges due to high risk of chronic inflammation and reduced cell mineralization levels. Herein, a core-shell nanofiber-based implant with significant pro-osteogenesis capability for treating skull defects is reported, which is hierarchically integrated with curcumin-loaded calcium carbonate nanoparticles (CaCO3@Cur NPs) in the outer layers and black phosphorus nanosheets (BPNSs) in the core compartments. The radical alignment of the integrated nanocomponents allows the sequential in situ release of the therapeutic agents in a controlled manner after implantation. Curcumin can repolarize M1 macrophages into M2 phenotypes for anti-inflammation purposes. Meanwhile, the released calcium and phosphate ions can promote the biomineralization of hydroxyapatite at the defect site and facilitate bone regeneration. Evaluations on cranial defect-bearing rat models demonstrated that the electrospun fibers in the present study substantially promoted restoration of the damaged skulls and inhibited inflammation in the wound bed. This strategy provides a new idea for the treatment of skull defects in the clinic.

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized pathologically by extracellular deposition of β-amyloid (Aβ) into senile plaques and intracellular accumulation of hyperphosphorylated tau (pTau) as neurofibrillary tangles. Clinically, AD patients show memory deterioration with varying cognitive dysfunctions. The exact molecular mechanisms underlying AD are still not fully understood, and there are no efficient drugs to stop or reverse the disease progression. In this review, we first provide an update on how the risk factors, including APOE variants, infections and inflammation, contribute to AD; how Aβ and tau become abnormally accumulated and how this accumulation plays a role in AD neurodegeneration. Then we summarize the commonly used experimental models, diagnostic and prediction strategies, and advances in periphery biomarkers from high-risk populations for AD. Finally, we introduce current status of development of disease-modifying drugs, including the newly officially approved Aβ vaccines, as well as novel and promising strategies to target the abnormal pTau. Together, this paper was aimed to update AD research progress from fundamental mechanisms to the clinical diagnosis and therapies.

Methods for high throughput discovery of fluoroprobes that recognize tau fibril polymorphs

Aggregation of microtubule-associated protein tau (MAPT/tau) into conformationally distinct fibrils underpins neurodegenerative tauopathies. Fluorescent probes (fluoroprobes), such as thioflavin T (ThT), have been essential tools for studying tau aggregation; however, most of them do not discriminate between amyloid fibril conformations (polymorphs). This gap is due, in part, to a lack of high-throughput methods for screening large, diverse chemical collections. Here, we leverage advances in protein adaptive differential scanning fluorimetry (paDSF) to screen the Aurora collection of 300+ fluorescent dyes against multiple synthetic tau fibril polymorphs. This screen, coupled with orthogonal secondary assays, revealed pan-fibril binding chemotypes, as well as fluoroprobes selective for subsets of fibrils. One fluoroprobe recognized tau pathology in ex vivo brain slices from Alzheimer's disease patients. We propose that these scaffolds represent entry points for development of selective fibril ligands and, more broadly, that high throughput, fluorescence-based dye screening is a platform for their discovery.

Are Women with Polycystic Ovary Syndrome at Increased Risk of Alzheimer Disease? Lessons from Insulin Resistance, Tryptophan and Gonadotropin Disturbances and Their Link with Amyloid-Beta Aggregation

Alzheimer disease, the leading cause of dementia, and polycystic ovary syndrome, one of the most prevalent female endocrine disorders, appear to be unrelated conditions. However, studies show that both disease entities have common risk factors, and the amount of certain protein marker of neurodegeneration is increased in PCOS. Reports on the pathomechanism of both diseases point to the possibility of common denominators linking them. Dysregulation of the kynurenine pathway, insulin resistance, and impairment of the hypothalamic-pituitary-gonadal axis, which are correlated with amyloid-beta aggregation are these common areas. This article discusses the relationship between Alzheimer disease and polycystic ovary syndrome, with a particular focus on the role of disorders of tryptophan metabolism in both conditions. Based on a review of the available literature, we concluded that systemic changes occurring in PCOS influence the increased risk of neurodegeneration.

Co-Assembled Nanoparticles toward Multi-Target Combinational Therapy of Alzheimer's Disease by Making Full Use of Molecular Recognition and Self-Assembly

The complex pathologies in Alzheimer's disease (AD) severely limit the effectiveness of single-target pharmic interventions, thus necessitating multi-pronged therapeutic strategies. While flexibility is essentially demanded in constructing such multi-target systems, for achieving optimal synergies and also accommodating the inherent heterogeneity within AD. Utilizing the dynamic reversibility of supramolecular strategy for conferring sufficient tunability in component substitution and proportion adjustment, amphiphilic calixarenes are poised to be a privileged molecular tool for facilely achieving function integration. Herein, taking β-amyloid (Aβ) fibrillation and oxidative stress as model combination pattern, a supramolecular multifunctional integration is proposed by co-assembling guanidinium-modified calixarene with ascorbyl palmitate and loading dipotassium phytate within calixarene cavity. Serial pivotal events can be simultaneously addressed by this versatile system, including 1) inhibition of Aβ production and aggregation, 2) disintegration of Aβ fibrils, 3) acceleration of Aβ metabolic clearance, and 4) regulation of oxidative stress, which is verified to significantly ameliorate the cognitive impairment of 5×FAD mice, with reduced Aβ plaque content, neuroinflammation, and neuronal apoptosis. Confronted with the extremely intricate clinical realities of AD, the strategy presented here exhibits ample adaptability for necessary alterations on combinations, thereby may immensely expedite the advancement of AD combinational therapy through providing an exceptionally convenient platform.

Single-Molecule Maps of Membrane Insertion by Amyloid-β Oligomers Predict Their Toxicity

The interaction of small Amyloid-β (Aβ) oligomers with the lipid membrane is an important component of the pathomechanism of Alzheimer's disease (AD). However, oligomers are heterogeneous in size. How each type of oligomer incorporates into the membrane, and how that relates to their toxicity, is unknown. Here, we employ a single molecule technique called Q-SLIP (Quencher-induced Step Length Increase in Photobleaching) to measure the membrane insertion of each monomeric unit of individual oligomers of Aβ42, Aβ40, and Aβ40-F19-Cyclohexyl alanine (Aβ40-F19Cha), and correlate it with their toxicity. We observe that the N-terminus of Aβ42 inserts close to the center of the bilayer, the less toxic Aβ40 inserts to a shallower depth, and the least toxic Aβ40-F19Cha has no specific distribution. This oligomer-specific map provides a mechanistic representation of membrane-mediated Aβ toxicity and should be a valuable tool for AD research.

Distinctive contribution of two additional residues in protein aggregation of Aβ42 and Aβ40 isoforms

Amyloid-β (Aβ) is one of the amyloidogenic intrinsically disordered proteins (IDPs) that self-assemble to protein aggregates, incurring cell malfunction and cytotoxicity. While Aβ has been known to regulate multiple physiological functions, such as enhancing synaptic functions, aiding in the recovery of the blood-brain barrier/brain injury, and exhibiting tumor suppression/antimicrobial activities, the hydrophobicity of the primary structure promotes pathological aggregations that are closely associated with the onset of Alzheimer's disease (AD). Aβ proteins consist of multiple isoforms with 37-43 amino acid residues that are produced by the cleavage of amyloid-β precursor protein (APP). The hydrolytic products of APP are secreted to the extracellular regions of neuronal cells. Aβ 1-42 (Aβ42) and Aβ 1-40 (Aβ40) are dominant isoforms whose significance in AD pathogenesis has been highlighted in numerous studies to understand the molecular mechanism and develop AD diagnosis and therapeutic strategies. In this review, we focus on the differences between Aβ42 and Aβ40 in the molecular mechanism of amyloid aggregations mediated by the two additional residues (Ile41 and Ala42) of Aβ42. The current comprehension of Aβ42 and Aβ40 in AD progression is outlined, together with the structural features of Aβ42/Aβ40 amyloid fibrils, and the aggregation mechanisms of Aβ42/Aβ40. Furthermore, the impact of the heterogeneous distribution of Aβ isoforms during amyloid aggregations is discussed in the system mimicking the coexistence of Aβ42 and Aβ40 in human cerebrospinal fluid (CSF) and plasma. [BMB Reports 2024; 57(6): 263-272].

Prominent Perspective on Existing Biological Hallmarks of Alzheimer's Disease

Biomarkers are the most significant diagnosis tools tending towards unique approaches and solutions for the prevention and cure of Alzheimer's Disease (AD). The current report provides a clear perception of the concept of various biomarkers and their prominent features through analysis to provide a possible solution for the inhibition of events in AD. Scientists around the world truly believe that crucial hallmarks can serve as critical tools in the early diagnosis, cure, and prevention, as well as the future of medicine. The awareness and understanding of such biomarkers would provide solutions to the puzzled mechanism of this neuronal disorder. Some of the argued biomarkers in the present article are still in an experimental phase as they need to undergo specific clinical trials before they can be considered for treatment.

Alzheimer's disease and clinical trials

Alzheimer's disease (AD) is spreading its root disproportionately among the worldwide population. Many genes have been identified as the hallmarks of AD. Based upon the knowledge, many clinical trials have been designed and conducted. Attempts have been made to alleviate the pathology associated with AD by targeting the molecular products of these genes. Irrespective of the understanding on the genetic component of AD, many clinical trials have failed and imposed greater challenges on the path of drug discovery. Therefore, this review aims to identify research and review articles to pinpoint the limitations of drug candidates (thiethylperazine, CT1812, crenezumab, CNP520, and lecanemab), which are under or withdrawn from clinical trials. Thorough analysis of the cross-talk pathways led to the identification of many confounding factors, which could interfere with the success of clinical trials with drug candidates such as thiethylperazine, CT1812, crenezumab, and CNP520. Though these drug candidates were enrolled in clinical trials, yet literature review shows many limitations. These limitations raise many questions on the rationale behind the enrollments of these drug candidates in clinical trials. A meticulous prior assessment of the outcome of clinical studies may stop risky clinical trials at their inceptions. This may save time, money, and resources.